Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis by Kraan, MC et al.
EXTENDED REPORT
Differential effects of leflunomide and methotrexate
on cytokine production in rheumatoid arthritis
M C Kraan, T J M Smeets, M J van Loon, F C Breedveld, B A C Dijkmans, P P Tak
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
See end of article for
authors’ affiliations
. . . . . . . . . . . . . . . . . . . . . . .
Correspondence to:
Professor P P Tak, Division
of Clinical Immunology
and Rheumatology,
Department of Internal
Medicine, University of
Amsterdam/Academic
Medical Centre,
Meibergdreef 9, 1105 AZ
Amsterdam, The
Netherlands; p.p.tak@
amc.uva.nl
Accepted 19 April 2004
Published online first
28 April 2004
. . . . . . . . . . . . . . . . . . . . . . .
Ann Rheum Dis 2004;63:1056–1061. doi: 10.1136/ard.2003.014738
Background: T cells have a pivotal role in RA. Leflunomide inhibits pyrimidine biosynthesis, to which T cells
are especially susceptible, and therefore may have a different cytokine profile than methotrexate.
Materials and methods: Serum samples of 100 patients with RA, treated with leflunomide (n = 50) or
methotrexate (n = 50), were collected at baseline, after 16 weeks and after 1 year’s treatment. Serum
levels of interleukin 6 (IL6), and interferon (IFN) c were determined by ELISA. Additionally, peripheral
blood mononuclear cells (PBMC) of five healthy volunteers and three patients with RA were isolated and
the effects of the active metabolite of leflunomide (A77-1726, 0–200 mmol/l) on cell proliferation and on
IL6 and IFNc production were determined by ELISA. In peripheral blood lymphocytes (PBL) and monocytes
(PBM) from two healthy volunteers the effects of A77-1726 on IL6 production were measured by ELISA and
PCR.
Results: Mean (SEM) serum levels of IFNc were significantly reduced after leflunomide treatment (baseline
43 (10) pg/ml; 1 year 29 (7) (p = 0.015), but there was no change in IL6 levels (baseline 158 (41), 1 year
151 (48)). Both IFNc and IL6 levels were significantly reduced after methotrexate treatment. This
observation was supported by in vitro experiments. The production of IFNc by PBL was inhibited by A77-
1726, but IL6 production by PBM was not inhibited.
Conclusion: The differential effect on IFNc and IL6 production supports the hypothesis that activated T cells
are preferentially inhibited by leflunomide. An explanation may be either inhibition of uridine synthesis or
effects on signal transduction pathways.
L
eflunomide inhibits both synovial inflammation and joint
destruction in patients with rheumatoid arthritis (RA).1–3
In vivo, leflunomide acts as a pro-drug and is quickly
metabolised into the active metabolite A77-1726 in the gut
wall and liver. Most of the in vitro pharmacodynamic studies
have, therefore, been conducted with the active metabolite
A77-1726 rather than with leflunomide.
The mechanism of action has been described in three
excellent reviews.4–6 In summary, at least two modes of
action of leflunomide have been documented: inhibition
of dihydro-orotate dehydrogenase (DHODH), by which
leflunomide influences the de novo pyrimidine biosynthesis,7
and interaction with primary and secondary signalling
events.8–10
The main target of leflunomide seems to be pyrimidine
biosynthesis, because leflunomide shows high affinity bind-
ing to DHODH, and, even at low concentrations, inhibits the
enzyme.6 DHODH is essential for the de novo synthesis of
uridine monophosphate (UMP), a precursor of pyrimidine
nucleotides. Resting lymphocytes have low levels of DHODH
and mainly use a salvage pathway for UMP to sustain
survival.7 Activation of lymphocytes gives a seven- to
eightfold increased demand for UMP, which makes these
cells susceptible to DHODH inhibition by leflunomide in the
absence of a salvage pathway.11 DHODH inhibition decreases
UMP levels, decreases DNA and RNA synthesis and,
consequently, inhibits cell proliferation and G1 phase cell
cycle arrest. Other cells are less affected by DHODH because
of the use of a salvage pathway. Another argument
supporting the proposed inhibitory effects of leflunomide
on T cells by DHODH inhibition is the reversal of the observed
effects by exogenous uridine in vitro.7 Further support is
found in the observation that the inhibition of de novo
pyrimidine biosynthesis by leflunomide is 100-fold stronger
than its effects on tyrosine kinases.6
Leflunomide also affects signal transduction,9 interferes
with cell-cell contact,12 and inhibits tumour necrosis factor a
(TNFa) induced activation of NF-kB.10 Moreover, studies of
leflunomide have shown that it affects neutrophil chemo-
taxis, which cannot directly be explained by effects on purine
nucleotides.13 Therefore, it has been suggested that the effects
on pyrimidine biosynthesis are associated with low doses of
leflunomide, whereas other mechanisms might be operative
at higher concentrations.4 6 In registration studies on the
treatment of active RA the comparator drug for leflunomide
was often methotrexate. The mechanism of action of
methotrexate in RA is currently not completely understood
but seems to be more than an effect on purine biosynthesis,
and appears to be not cell type specific. Whereas the effects of
methotrexate on interleukin (IL)614 and interferon c (IFNc)15
levels have previously been demonstrated, there are no data
on leflunomide. To provide insight into the beneficial effects
of leflunomide in patients with RA we examined the effects
of leflunomide on cytokine production by mononuclear cells.
MATERIALS AND METHODS
In vivo study
A total of 100 (50 treated with leflunomide and 50 treated
with methotrexate) patients were selected from 999 patients
with RA who participated in a prospective, double blind,
randomised clinical trial comparing leflunomide and metho-
trexate.16 Firstly, sites with a large number of patients
Abbreviations: CRP, C reactive protein; DAS, disease activity score;
DHODH, dihydro-orotate dehydrogenase; ELISA, enzyme linked
immunosorbent assay; IFN, interferon; IL, interleukin; LPS,
lipopolysaccharide; mAb, monoclonal antibody; PBL, peripheral blood
lymphocytes; PBM, peripheral blood monocytes; PBMC, peripheral
blood mononuclear cells; PCR, polymerase chain reaction; PHA,
phytohaemagglutinin; RA, rheumatoid arthritis; TNF, tumour necrosis
factor; UMP, uridine monophosphate
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enrolled were selected to minimise variance in sampling,
processing, and sending to a centralised laboratory. Samples
were stored at 280 C˚ and shipped to our centre for analysis
4–5 years after sampling. No data are available on stability,
but all samples were subject to the same conditions. As a
result the serum samples of six study sites were used. For all
100 patients (50 leflunomide, 50 methotrexate) serum
samples from baseline, after 4 months, and after 1 year were
available and tested. Clinical variables included the disease
activity score (DAS) and C reactive protein (CRP), measured
at the same times. Patients were treated with either
leflunomide 20 mg/day after a loading dose of 100 mg/day
for the first 3 days or methotrexate 15 mg/week (initial dose
7.5 mg/week, increased to 10 mg/week 4 weeks after base-
line, and increased to 15 mg/week 8 weeks after baseline). At
baseline all disease modifying antirheumatic drugs were
washed out and only concomitant non-steroidal anti-
inflammatory drug and low dose prednisone ((10 mg/day)
treatment was allowed
Measurement of cytokine production in patients with
RA
The in vivo production of IL6 was measured by enzyme linked
immunosorbent assay (ELISA) using a monoclonal anti-
human IL6 antibody (R&D catalogue No MAB206), and IFNc
was measured by ELISA using a monoclonal antihuman IFNc
antibody (R&D catalogue No DIF50). For both assays the
manufacturer’s specifications were used.
In vitro experiments
To investigate the observations made in vivo in more detail
we tested the effects of methotrexate and A77-1726 on
peripheral blood mononuclear cells (PBMC), peripheral blood
lymphocytes (PBL), and peripheral blood monocytes (PBM)
in vitro. A77-1726 (the active metabolite of HWA486)
obtained in powder form (kindly provided by Dr RR
Bartlett, Aventis Pharma, Wiesbaden, FRG), was diluted at
the appropriate concentrations (0.1–200 mmol/l, clinically
relevant concentration is ¡20 mmol/l).
Cells
PBMC of five healthy volunteers and three patients with RA
were prepared using Ficoll density centrifugation. No major
differences were found and, therefore, pooled results are
presented of experiments in duplicate. In two healthy
volunteers the fractions of PBL and PBM were further
purified by countercurrent centrifugation; the preparations
contained more than 80% PBL or PBM, and the viability was
more than 95% as assessed by trypan blue exclusion.
Stimulation
Cells were stimulated with 5 mg/ml phytohaemagglutinin
(PHA; Murex Diagnostics Ltd, Dartford, UK), 5 mg/ml
lipopolysaccharide (LPS; Sigma, St Louis, USA), 5 mg/ml
anti-CD2 monoclonal antibody (mAb) (CLB-CD2), 5 mg/ml
anti-CD3 mAb Okt3 (CLB-CD3, CLB, Amsterdam, The
Table 1 Demographics, clinical data, and cytokine measurements of the patients with RA studied
Leflunomide* (n = 50) Methotrexate* (n = 50)
Baseline 4 Months p Value 1 Year p Value Baseline 4 Months p Value 1 Year p Value
DAS 6.9 (0.1) 5.6 (0.2) ,0.0001 5.2 (0.2) ,0.0001 7.0 (0.1) 5.3 (0.2) ,0.0001 4.2 (0.2) ,0.0001
CRP (mg/l) 5.3 (0.9) 2.2 (0.5) ,0.0001 2.1 (0.5) ,0.0001 3.5 (0.4) 1.3 (0.2) ,0.0001 0.9 (0.2) ,0.0001
Interferon c (pg/ml) 43 (10) 38 (8) NS 29 (7) 0.015 57 (10) 44 (7) NS 36 (6) 0.046
Interleukin 6 (pg/ml) 158 (41) 180 (67) NS 151 (48) NS 107 (23) 93 (25) 0.02 80 (20) 0.05
Results are given as mean (SEM).
*Patients receiving leflunomide were aged 62 (range 46–75) years, with mean (SEM) disease duration 49 (6) months; patients receiving methotrexate were aged
58 (22–74) years, with disease duration 42 (5) months.
Figure 1 (A) Incorporation of [3H]thymidine by PBMC of healthy
donors and patients with RA after stimulation with LPS. Graph depicts the
number of counts as measured after 24 hours of incubation in the
presence of various concentrations of leflunomide (0–100 mmol/l).
(B) Production of IFNc (pg/ml) by PBMC after 36 hours. Depicted are
controls and cells stimulated with PHA in the presence of various
concentrations of leflunomide (0–100 mmol/l). (C) Production of IL6
(pg/ml) by PBMC after 8 hours. Depicted are controls and cells
stimulated with PHA in the presence of various concentrations of
leflunomide (0–100 mmol/l).
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Netherlands), and 5 mg/ml anti-CD28 mAb 15E8 (CLB-
CD28/1). The various stimuli were added to the PBMC,
PBL, or PBM together with A77-1726 and tests carried out at
intervals between 4 and 72 hours.
Proliferation experiments
Overnight, 96 well culture plates (Greiner, Alphen a/d Rijn,
The Netherlands) were coated with anti-CD3 mAb or LPS.
PBMC and PBL (two donors) were plated (26105 cells/well)
and incubated with or without A77-1726 for 48 hours
(24 hours after initiation 20 mCi [3H]thymidine/ml, 0.05 ml/
well, was added). Cells were harvested and the rate of DNA
synthesis was measured. Experiments were performed in
triplicate.
Cytokine measurement
Experiments were performed in 24 well tissue culture plates
(16106 cells/well). For the determination of IL6 an ELISA
was used with antihuman IL6 mAb (mAb16; Department of
Nephrology LUMC, Leiden, The Netherlands); sensitivity was
1 pg/ml. For the determination of IFNc an ELISA was used
with anti-IFNc mAb (MD2, CLB); sensitivity was 0.2 ng/ml.
For all experiments cell vitality and cell death were
estimated by trypan blue exclusion and a lactate dehydro-
genase test (Boehringer Mannheim Cytotoxicity kit, catalo-
gue No 1 644 793). The results obtained could not be
attributed to the effects of cell death in any of the
experiments. Addition of uridine together with A77-1726 at
incubation abolished all observed effects of A77-1726 alone.
RNA preparation, cDNA synthesis, semiquantitative
polymerase chain reaction (PCR) on PBM
In PHA stimulated PBM, RNA encoding IL6 and b2-
microglobulin was measured by PCR as described pre-
viously.17 In brief, total RNA was isolated with RNAzol
(Cinna/Biotecx Laboratories Inc, Houston, TX, USA), accord-
ing to the manufacturer’s description. Total RNA (2 mg) was
converted into first strand cellular cDNA using oligo-dT
primers (Gibco BRL, Breda, The Netherlands). Relative
quantification of mRNA was based on the usage of synthetic
DNA (st-DNA=pQA-1) that contains sequences that are
complementary to the cytokine-specific PCR primers used
and result in an amplification of different length than the
specific amplicon. Titration experiments were carried out
with various amounts of synthetic DNA added to a fixed
amount of cellular cDNA. The titration used the intensity of
the internal standard product and the specific IL6 PCR was
equal, so the amount of IL6 product could be estimated. b2-
Microglobulin mRNA was used for standardisation of the
different RNA samples. The ratio between IL6 mRNA and b2-
microglobulin mRNA was used to assess the relative levels of
the specific mRNA between the various samples. The PCR
mix (final volume 40 ml) consisted of 1 ml of a 1:10 dilution
of cellular cDNA, 2.5 nM of each dNTP, 50 mM KCl, 10 mM
Tris-HCL (pH 8.4), 2 mM MgCl2, 0.06% bovine serum
albumin, 0.87 U DNA taq polymerase (Perkin Elmer,
Gouda, The Netherlands), and 10 pmol of each specific sense
and antisense primer (Isogen Bioscience, Maarssen, The
Netherlands): b2-microglobulin sense primer 59GCAGCAGCG
AATGGAAAGTC 39, b2-microglobulin antisense primer
59GATCCTGCTTACATGGTCTCG 39, TNFa sense primer
59ACCCGCCTGTAGCCCATGTT 39, TNFa antisense primer
59AAAGTAGACTTGCCCAGACT 39.
Statistical analysis
Wilcoxon signed rank test for paired samples was used to test
the changes from the baseline measurement. Student t tests
were used to compare the two treatment groups. Spearman’s
test were used to test correlations between CRP and IL6.
RESULTS
Study patients
Table 1 shows the demographic and clinical data of the
patients. All patients had active disease at baseline, as
measured by the mean (SEM) DAS of 6.9 (0.1) for the
leflunomide patients and 7.0 (0.1) for the methotrexate
patients, with a significant reduction after 4 months, and
after 1 year in both leflunomide and methotrexate treated
patients (table 1). The CRP levels were significantly reduced
in both leflunomide and methotrexate patients (table 1), but
in line with previous results18 the CRP levels were signifi-
cantly lower after 1 year of treatment with methotrexate
(p=0.014).
In vivo cytokine measurements
Leflunomide significantly inhibited mean (SEM) IFNc
production: baseline 43 (10) pg/ml, 1 year 29 (7) pg/ml
(p=0.015), whereas IL6 remained unchanged (baseline 158
(41) pg/ml, 1 year 151 (48) pg/ml) (table 1). Methotrexate
also significantly inhibited IFNc levels: baseline 57 (10) pg/
ml to 36 (6) pg/ml after 1 year (p=0.046), but in contrast
with the findings in the leflunomide treated patients IL6 was
also inhibited significantly at 4 months and after 1 year:
baseline 107 (23) pg/ml, 4 months 93 (25) pg/ml (p=0.020),
and 1 year 80 (20) pg/ml (p=0.05) (table 1).
At baseline there was a significant correlation between
serum IL6 levels and serum CRP (rs= 0.296, p=0.003); this
correlation was sustained at 4 months for methotrexate
patients (rs= 0.579, p,0.0001), but not for leflunomide
(rs= 0.274, NS). After 1 year there was no significant
correlation between CRP levels and IL6 in either leflunomide
or methotrexate treated patients.
In vitro studies
A77-1726 completely inhibited mitogen induced prolifera-
tion of PBMC by LPS and PHA (PHA and patients with
RA, control 59 650 (8835) counts (mean (SEM)), 100 mM
Table 2 IFNc production (pg/ml) by PBMC of patients with RA and healthy controls at
baseline and 48 hours after stimulation with PHA 5 mg/ml
A77-1726
(mmol/l)
Baseline 48 Hours
Controls Patients with RA Controls Patients with RA
(n = 5) (n = 3) (n = 5) (n = 3)
0 0 (0) 0 (0) 18549 (2772) 4484 (120)
1 12 (36) 0 (0) 13500 (7267) 4144 (12)
10 0 (0) 0 (0) 15990 (6193) 4474 (198)
25 0 (0) 0 (0) 10950 (6383) 4106 (258)
50 0 (0) 0 (0) 7830 (4848) 3488 (320)
100 0 (0) 0 (0) 6810 (2001) 1888 (32)
Results are given as mean (SEM).
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Figure 2 Analysis of b2-microglobulin and IL6 mRNA levels in PHA stimulated monocytes. A constant volume of the b2-microglobulin and IL6 cellular
cDNA products was mixed with graded amounts of a known concentration of pQA1 DNA (st-DNA) containing the specific sequences for the b2-
microglobulin and IL6 PCR primers. PCR was performed, and the PCR products were separated by electrophoresis on a 1% agarose gel and visualised
after ethidium bromide staining under ultraviolet light. The concentration of st-DNA that gave an amount of PCR product equal to that of the cellular
DNA b2-microglobulin or IL6 PCR products, respectively, was determined. The intensity of the bands was quantified by densitometry. The density of the
st-DNA was expressed as a percentage of the total density of st-DNA and cellular cDNA. Results are presented in the absence of A77-1726, and the
presence of 10 mM and 100 mM A77-1726.
Table 3 Interleukin 6 production (pg/ml) by PBMC of patients with RA and healthy controls at baseline and 24 hours after
stimulation with PHA 5 mg/ml. Also given are measurements in density centrifugation isolated PBM of healthy controls 8 hours
after stimulation with PHA and PBL 16 hours after stimulation with aCD3/aCD28
A77-1726
(mmol/l)
PBMC
(unstimulated)
PBMC
(stimulated with PHA)
PBM
(stimulated with PHA)
PBL (stimulated
with aCD3/aCD28)
Baseline 24 Hours 8 Hours 16 Hours
Controls Patients with RA Controls Patients with RA Controls Controls
(n = 5) (n = 3) (n = 5) (n = 3) (n = 2) (n = 2)
0 0 (0) 110 (11) 13967 (4937) 12880 (1640) 24306 (3761) 2320 (420)
1 0 (0) 183 (97) 12033 (3134) 10700 (680) ND ND
10 0 (0) 0 (0) 15067 (3162) 10035 (815) ND 2070 (185)
25 0 (0) 175 (175) 14600 (2872) 11700 (1200) ND ND
50 0 (0) 198 (53) 12633 (4513) 16745 (4685) 25325 (2118) 2110 (340)
100 0 (0) 133 (83) 21300 (4198) 16385 (725) 57203 (18221) 2370 (255)
Results are given as mean (SEM).
ND, not done.
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A77-1726 1744 (661); p,0.05) (fig 1A) in a dose dependent
fashion in both patients with RA and healthy volunteers.
A77-1726 reduced IFNc production by PBMC after
stimulation with PHA in a dose dependent way in healthy
controls (control 18 549 (2772) pg/ml, 100 mM A77-1726
6810 (2001) pg/ml; p,0.05) (table 2, fig 1B) and patients
with RA (control 4484 (120) pg/ml, 100 mM A77-1726 1888
(32) pg/ml; p,0.05). Stimulation with anti-CD3/anti-CD28
resulted in comparable results (fig 1B). In PBL there was also
a dose dependent inhibition (control 33 020 pg/ml, 100 mM
A77-1726 6550 pg/ml). PBM were not tested for IFNc
production.
Consistent with the in vivo data we observed no effect of
A77-1726 on production of IL6 by PBMC after stimu-
lation with PHA (control 13 967 (4937) pg/ml (mean
(SEM), 100 mM A77-1726 21 300 (4198) pg/ml (fig 1C).
Stimulation with LPS resulted in comparable results (fig 1C).
In addition, A77-1726 did not affect IL6 gene expression or
protein production by PBM (baseline 24 306 (3761) pg/ml,
100 mM A77-1726 57 203 (18 221) pg/ml) (fig 2). As
expected, IL6 production by PBL was very low at baseline
and did not change in the presence of A77-1726 (table 3).
DISCUSSION
We observed inhibition of IFNc but not of IL6 in patients
with RA treated with leflunomide and, as previously
described, inhibition of IL614 and IFNc15 by methotrexate.
Stimulation of PBMC, PBL, and PBM confirmed the lack of
effect on IL6 production with a dose dependent inhibition of
IFNc production and proliferation by A77-1726.8 19–21
An understanding of the mechanism of action of new
immunomodulating drugs, in the treatment of RA can be
obtained from data on in vitro and in vivo cytokine
production, which can provide vital information on the
targets of the investigated substance.10 As cytokines may
reflect differential pharmacodynamic effects of leflunomide
and methotrexate on inflammation we focused on the T cell
related cytokine IFNc and the macrophage related cytokine
IL6.
Serum IL6 levels of patients with RA have been associated
with disease outcome,22 but failed to correlate with disease
activity in patients with RA treated with methotrexate,23 as
demonstrated in our study. During phase III studies with
leflunomide a remarkable observation was the significant
clinical improvement with only modest changes in erythro-
cyte sedimentation rate and CRP, especially when compared
with methotrexate. This relative lack of change in acute
phase response after leflunomide treatment is consistent
with a limited effect on IL6 production and a more T cell
directed mechanism of action.24
The T cell derived cytokine IFNc is also produced by natural
killer cells (NK cells) and is involved in nearly all phases of
inflammation and in the regulation of inflammatory
responses. It has effects on macrophage, B cell, and
neutrophil function. The inhibition of IFNc, as seen in this
study, might be the result of inhibition of DHODH, which
impairs T cell function with, as secondary effect, inhibition of
monocyte/macrophage function. This is supported by the
inhibition which occurs at concentrations of active metabo-
lite present in patients with RA.1 The effects of leflunomide
on IFNc production shown in this study confirm and extend
previous work in animal models of arthritis.27 Leflunomide
has also been shown to interfere with IFNc induced inducible
nitric oxide synthase activation and nitric oxide production in
fibroblast,26 probably through the MEK/MAP pathway.27
Unfortunately, we could not directly compare in vitro and
in vivo use of methotrexate owing to technical problems.
However, the limited reports available suggest that the results
in an vitro model are comparable with those we observed in
vivo.28 29 Within this context it is important to mention that
the effects of methotrexate as purine antagonist are probably
limited,30 and the beneficial effects are more likely to be
mediated through adenosine.31–33 We observed a clear effect of
leflunomide on the proliferation of PBMC without signs of
cell death. Other authors have demonstrated that T cells are
inhibited by leflunomide in the G1-S phase. Previously, these
phenomena were attributed to an inhibitory effect on
phosphorylation of tyrosine kinases, resulting in interference
with signalling events. More recent data point strongly
towards inhibition of the enzyme DHODH, resulting in a
negative effect on pyrimidine biosynthesis and antiprolifera-
tive effects. An overview of all the data available suggests
that the inhibitory effects of leflunomide are due to a
combination of both inhibition of pyrimidine biosynthesis
and interference with signalling events.6 The relative con-
tribution of each mechanism of action might be dependent
on the concentrations of the drug.25
In conclusion, we observed a differential effect on cytokine
production by leflunomide with a significant inhibition of
IFNc production with unchanged IL6 levels. This observation
supports the hypothesis that leflunomide preferentially
affects activated T cells. It also supports the clinical
observation of different pharmacodynamic profiles for
methotrexate and leflunomide.1
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